FDA Clearance Tracker · K192659
Omnipod Insulin Management System, Omnipod DASH Insulin Management System
Last checked: Nov 20, 2026Latest source record: Oct 21, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Oct 21, 2019
Substantially Equivalent
Time to decision
26 days
Received Sep 25, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K192659
- Device name
- Omnipod Insulin Management System, Omnipod DASH Insulin Management System
- Applicant
- Insulet Corporation
- Applicant location
- Acton, MA
- Received
- Sep 25, 2019
- Decided
- Oct 21, 2019
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Pump, Infusion, Insulin (LZG)
- Device class
- Class II
- Regulation
- 21 CFR 880.5725
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LZG. The earliest in FDA's data is K884978, decided Jun 21, 1989.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K192659
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Insulet Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Omnipod 6 algorithm510(k)
K261461 · Decided Jun 29, 2026 · 56 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- Omnipod 5 algorithm510(k)
K251779 · Decided Dec 3, 2025 · 176 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
- SmartAdjust Technology510(k)
K241777 · Decided Aug 26, 2024 · 67 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.